A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

被引：0
|
作者：
Noelle K. LoConte
James P. Thomas
Dona Alberti
Jennifer Heideman
Kimberly Binger
Rebecca Marnocha
Kyle Utecht
Peter Geiger
Jens Eickhoff
George Wilding
Jill Kolesar
机构：
[1] University of Wisconsin Paul P. Carbone Comprehensive Cancer Center,
[2] The Ohio State University Comprehensive Cancer Center,undefined
[3] University of Wisconsin School of Pharmacy,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 63卷
关键词：
Bortezomib; Doxorubicin; Ubiquitination; Proteasome inhibition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：109 / 115
页数：6
相关论文
共 50 条
  • [1] A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer
    LoConte, Noelle K.
    Thomas, James P.
    Alberti, Dona
    Heideman, Jennifer
    Binger, Kimberly
    Marnocha, Rebecca
    Utecht, Kyle
    Geiger, Peter
    Eickhoff, Jens
    Wilding, George
    Kolesar, Jill
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 109 - 115
  • [2] Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies
    Falchook, G. S.
    Duvic, M.
    Hong, D. S.
    Wheler, J.
    Naing, A.
    Lim, J.
    Kurzrock, R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1117 - 1126
  • [3] Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies
    G. S. Falchook
    M. Duvic
    D. S. Hong
    J. Wheler
    A. Naing
    J. Lim
    R. Kurzrock
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1117 - 1126
  • [4] Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
    John Hayslip
    Uzair Chaudhary
    Mark Green
    Mario Meyer
    Steven Dunder
    Carol Sherman
    Shanta Salzer
    Andrew Kraft
    Alberto J Montero
    BMC Cancer, 7
  • [5] Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
    Ryan, David P.
    Appleman, Leonard J.
    Lynch, Thomas
    Supko, Jeffrey G.
    Fidias, Panagiotis
    Clark, Jeffrey W.
    Fishman, Mayer
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kashala, Oscar
    Cusack, James, Jr.
    Eder, Joseph P.
    CANCER, 2006, 107 (10) : 2482 - 2489
  • [6] Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies
    Schenk, Erin
    Hendrickson, Andrea E. Wahner
    Northfelt, Donald
    Toft, David O.
    Ames, Matthew M.
    Menefee, Michael
    Satele, Daniel
    Qin, Rui
    Erlichman, Charles
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1251 - 1256
  • [7] A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    Schelman, William R.
    Traynor, Anne M.
    Holen, Kyle D.
    Kolesar, Jill M.
    Attia, Steven
    Hoang, Tien
    Eickhoff, Jens
    Jiang, Zhisheng
    Alberti, Dona
    Marnocha, Rebecca
    Reid, Joel M.
    Ames, Matthew M.
    McGovern, Renee M.
    Espinoza-Delgado, Igor
    Wright, John J.
    Wilding, George
    Bailey, Howard H.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1539 - 1546
  • [8] A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R. Schelman
    Anne M. Traynor
    Kyle D. Holen
    Jill M. Kolesar
    Steven Attia
    Tien Hoang
    Jens Eickhoff
    Zhisheng Jiang
    Dona Alberti
    Rebecca Marnocha
    Joel M. Reid
    Matthew M. Ames
    Renee M. McGovern
    Igor Espinoza-Delgado
    John J. Wright
    George Wilding
    Howard H. Bailey
    Investigational New Drugs, 2013, 31 : 1539 - 1546
  • [9] A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
    Dees, E. Claire
    O'Neil, Bert H.
    Lindley, Celeste M.
    Collichio, Frances
    Carey, Lisa A.
    Collins, Jason
    Riordan, William J.
    Ivanova, Anastasia
    Esseltine, Dixie
    Orlowski, Robert Z.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 99 - 107
  • [10] A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
    E. Claire Dees
    Bert H. O’Neil
    Celeste M. Lindley
    Frances Collichio
    Lisa A. Carey
    Jason Collins
    William J. Riordan
    Anastasia Ivanova
    Dixie Esseltine
    Robert Z. Orlowski
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 99 - 107
12345